BioTuesdays

Category - Markets

Dyadic
Markets

Dawson James halves Dyadic PT to $6 from $12

Dawson James reduced its price target for Dyadic (NASDAQ:DYAI) to $6 from $12, citing uncertainty about the potential of its COVID-19 vaccine. The stock closed at $3.73 on May 14. “DYAI-100 (COVID) is advancing to human...

May 17, 2021
Annovis Logo
Markets

Maxim ups Annovis Bio PT to $45 from $12

Maxim Group raised its price target for Annovis Bio (NYSE American: ANVS) to $45 from $12, citing upcoming Phase 2a data evaluating ANVS401 in Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients. The stock...

May 13, 2021
4D-Pharma-PLC
Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021
Catabasis Pharma
Markets

Ladenburg starts Catabasis Pharma at buy; PT $6

Ladenburg Thalmann launched coverage of Catabasis Pharmaceuticals (NASDAQ:CATB) with a “buy” rating and price target of $8. The stock closed at $1.78 on May 11. Catabasis is a Boston-based biotechnology company focused...

May 12, 2021
Intercept-Pharma
Markets

Cantor cuts Intercept Pharma PT to $23 from $45

Cantor Fitzgerald reduced its price target for Intercept Pharmaceuticals (NASDAQ:ICPT) to $23 from $45 and maintained its “neutral” rating, citing first quarter financial results “which we think highlighted a lot of the...

May 7, 2021
CTIBiopharmaLogo
Markets

Stifel starts CTI Biopharma at buy; PT $5.50

Stifel initiated coverage of CTI Biopharma (NASDAQ:CTIC) with a “buy” rating and price target of $5.50. The stock closed at $2.34 on May 5. “We think the bull/bear debate on CTI Biopharma centers around the size of the...

May 6, 2021
iTeos Logo
Markets

HCW starts iTeos Therapeutics at buy; PT $37

H.C. Wainwright launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with a “buy” rating and $37 price target. The stock finished at $23.03 on May 4. ITeos Therapeutics, which is developing next-generation immuno...

May 5, 2021
Mereo-BioPharma
Markets

BTIG starts Mereo Biopharma at buy; PT $10

BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...

May 5, 2021
Markets

Maxim doubles BioLineRx PT to $10 from $5

Maxim Group raised its price target for BioLineRx (NASDAQ:BLRX) to $10 from $5 on positive top-line data from the company’s Phase 3 GENESIS trial. The stock was quoted at $5.30, up $2.11, in afternoon trading on...

May 4, 2021